Sec Form 4 Filing - El-Hibri Fuad @ Aptevo Therapeutics Inc. - 2021-12-03

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
El-Hibri Fuad
2. Issuer Name and Ticker or Trading Symbol
Aptevo Therapeutics Inc. [ APVO]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X __ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle)
C/O APTEVO THERAPEUTICS INC., 2401 4TH AVENUE, SUITE 1050
3. Date of Earliest Transaction (MM/DD/YY)
12/03/2021
(Street)
SEATTLE, WA98121
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/03/2021 J( 1 ) 107,807 A $ 0 107,807 I See Footnote( 2 )
Common Stock 12/03/2021 J( 1 ) 9,819 A $ 0 9,819 I See Footnote( 3 )
Common Stock 12/03/2021 J( 1 ) 7,373 A $ 0 7,373 I See Footnote( 4 )
Common Stock 80,324 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
El-Hibri Fuad
C/O APTEVO THERAPEUTICS INC.
2401 4TH AVENUE, SUITE 1050
SEATTLE, WA98121
X
Signatures
/s/ Carl A. Valenstein, attorney-in-fact 12/07/2021
Signature of Reporting Person Date
Explanation of Responses:
( 1 )On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 5,880 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac.
( 2 )Held by the Yahia Fuad El-Hibri Revocable Trust, for which the reporting person serves as the Trustee. Comprised of (i) 59,253 shares of the Issuer's common stock previously reported as beneficially owned by Intervac and (ii) 48,554 shares of the Issuer's common stock previously reported as beneficially owned by BioVac. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the Yahia Fuad El-Hibri Revocable Trust except to the extent of his pecuniary interest therein.
( 3 )Held by the El-Hibri Family Trust, for which the reporting person's wife serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Family Trust except to the extent of his pecuniary interest therein.
( 4 )Held by the El-Hibri Decedents Trust, for which the reporting person serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Decedents Trust except to the extent of his pecuniary interest therein.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.